As for the observed effect of the combination therapy, BRAF and MEK inhibitors have shown significant improvements in clinical outcomes in BRAFV600E-mutant melanoma [34–40], non-small-cell lung cancer [41], and ATC [42]. Here, MAP2K7 is linked to melanoma.